Among breast cancer subtypes, triple-negative breast cancer (TNBC) poses significant challenges due to the absence of expression (or minimal expression) of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth factor receptor-2 (HER2) overexpression, limiting treatment options to non-targeted chemotherapy. This evidence concerns the gene PGR and breast cancer.